Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Janux Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Janux Therapeutics, Inc.

JANX

Janux Therapeutics, Inc.

About Janux Therapeutics, Inc.

Janux Therapeutics is a biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary TRACTr and TRACIr platforms create bispecific biologics designed to target solid tumors with enhanced safety, reduced toxicity, and extended half-life. Focused on cancers like prostate, colorectal, and lung, the company aims to deliver off-the-shelf, tumor-specific treatments that activate immune responses precisely within the tumor microenvironment.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Janux Therapeutics, Inc.

1
1
Janux Therapeutics, Inc. Janux Therapeutics Reports $3.7M Collaboration Revenue and $24.4M Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Janux Therapeutics, Inc. Janux Therapeutics Reports Increased Net Loss and Stable Revenue in Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Janux Therapeutics, Inc. Janux Therapeutics Reports Q3 2025 Financial Results with Increased Collaboration Revenue and Rising Operating Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Janux Therapeutics, Inc. Janux Therapeutics Reports No Revenue and Increased Losses in Latest Financial Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Janux Therapeutics, Inc. Janux Therapeutics Reports $23.5 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Janux Therapeutics, Inc. Janux Therapeutics Reports Significant Financial Developments, Net Loss Widens in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments